Streetbeat News

Stock Prices

ATOMUSD

BTCUSD

ETHUSD

IOTAUSD

LDOUSD

MKRUSD

XECUSD

Bitcoin and Ethereum prices moved lower, trading below $27,200 and $1,600 respectively. The U.S. Producer Price Index (PPI) increased 0.5% month-over-month in September, above market expectations of 0.3%. The global crypto market cap fell to $1.06 trillion, a 24-hour decline of 0.6%. Render was the top gainer, while XDC Network was the biggest loser.

Portfolio Pulse from Lisa Levin

October 11, 2023 | 1:32 pm

CHPT

ChargePoint has raised $232M to support its path to profitability in 2024. This includes $175M of new equity committed by institutional investors via the company's 'at-the-market' offering facility and $57M of new equity raised in Q3 of FY2024 via the ATM. The terms of outstanding $300M convertible notes have also been adjusted.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:32 pm

AAPL

BTCUSD

TSLA

Bitcoin miners have sold off 20,000 BTC in a week, marking the largest sell-off since April. Cathie Wood's Ark Invest continues to reduce its Tesla holdings, selling more than $8M worth of shares. Apple's support for the Right to Repair law in California has been enacted. Analysts are concerned about Apple's Q4 results as its stock takes a dive. Tesla's Q3 earnings report is under scrutiny, with analysts speculating about potential stock selloff due to margin erosion.

Portfolio Pulse from Akanksha Bakshi

October 11, 2023 | 1:31 pm

TGVC

TG Venture has received a notice from Nasdaq stating that it no longer meets the listing rule which requires listed companies to maintain a minimum of 400 total holders.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:29 pm

GSK

GSK plc has settled the Cantlay/Harper case filed in California state court, which was set to begin trial on November 13. This follows the resolution of the final three breast cancer bellwether cases in California, exempting GSK from further pre-trial hearings. Last year, the plaintiff dismissed GSK's first scheduled Zantac related-cancer trial. Citi analysts estimate that GSK will settle all the Zantac cases against it for a total of about $5 billion in Q1 2024.

Portfolio Pulse from Vandana Singh

October 11, 2023 | 1:27 pm

HRMY

ZYNE

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has completed its acquisition of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) for $60 million. The deal includes potential additional payments of up to $140 million subject to the achievement of specific milestones. Zynerba is known for its pharmaceutically produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. Its lead candidate, Zygel, could serve 80,000 U.S. patients diagnosed with Fragile X syndrome and another 80,000 diagnosed with 22q deletion syndrome.

Portfolio Pulse from Jelena Martinovic

October 11, 2023 | 1:25 pm

TPST

Tempest Therapeutics Inc (NASDAQ:TPST) released new results from an ongoing Phase 1b/2 study of TPST-1120 in the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC). The study shows TPST-1120's clinical superiority in multiple endpoints when combined with atezolizumab and bevacizumab. The confirmed objective response rate was 30% for the TPST-1120 arm versus 13.3% for the control arm. The progression-free survival was a median of 7 months for the TPST-1120 arm versus 4.27 months for the control arm. TPST shares are up 800.40% at $2.16 during the premarket session on the last check Wednesday.

Portfolio Pulse from Vandana Singh

October 11, 2023 | 1:24 pm

AAPL

CPI

META

NFLX

NVDA

PLTR

PPI

QQQ

TSLA

USO

The article lists the top 10 trending stocks on WallStreetBets as of October 11, 2023. The stocks mentioned include AAPL, CPI, META, NFLX, NVDA, PLTR, PPI, QQQ, TSLA, and USO.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:21 pm

SPY

USO

VGK

Russian President Vladimir Putin stated that without oil supply cuts, the price of oil could have fallen below $50 per barrel. He also mentioned that the OPEC+ deal is likely to continue.

Portfolio Pulse from Charles Gross

October 11, 2023 | 1:19 pm

ANAB

AnaptysBio is set to present Phase 1 data on ANB032, its BTLA agonist antibody, at the 32nd EADV Congress. This could potentially impact the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:16 pm